Xintela
0,292 SEK +1,39%1 investor følger denne virksomhed
Xintela is active in biotechnology. The company's expertise is found in regenerative medicine, as well as the treatment of cancer, articular cartilage damage, and brain tumors. The research is based on the development of protein molecules that have the capacity to sense changes in the surface of cells, which enables the identification of the stem cells that are about to develop into cartilage cells. The company was founded in 2009 and is headquartered in Lund.
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
First North Stockholm
XINT
Daglig lav / høj pris
0,278 / 0,294
SEK
Markedsværdi
166,08 mio. SEK
Aktieomsætning
25,85 t SEK
Volumen
91 t
Seneste videoer
Finanskalender
Delårsrapport
30.08.2024
Delårsrapport
22.11.2024
Årsrapport
28.02.2025
Større aktionærerKilde: Millistream Market Data AB
Ejer | Kapital | Stemmer |
---|---|---|
Flerie Invest AB | 55,7 % | 55,7 % |
Avanza Pension | 5,1 % | 5,1 % |
Premium
This content is for our Premium customers only.
ViserAlle indholdstyper
Xintela AB Interim Report January - March 2024
Xintela and EQGen Biomedical to collaborate to develop EQSTEM stem cell treatment for horses
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools